What analysts say:
- Buy, sell, or hold?: Analysts are bullish on Greatbatch, as two analysts rate it as a buy and only one analyst rate it as a sell. Analysts don't like Greatbatch as much as competitor ZOLL Medical overall. That rating hasn't budged in three months as analysts have remained unchanged in their opinion of the stock.
- Revenue forecasts: On average, analysts predict $140.9 million in revenue this quarter. That would represent a rise of 0% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.43 per share. Estimates range from $0.41 to $0.44.
What our community says:
CAPS All-Stars are solidly behind the stock, with 88.2% giving it an "outperform" rating. The community at large concurs with the All-Stars, with 85.5% granting it a rating of "outperform." Fools are bullish on Greatbatch, though the message boards have been quiet lately with only 34 posts in the past 30 days. Despite the majority sentiment in favor of Greatbatch, the stock has a middling CAPS rating of three out of five stars.
Revenue has now gone up for three straight quarters.
One final thing: If you want to keep tabs on Greatbatch movements, and for more analysis on the company, make sure you add it to your watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.